Innovative Therapeutic Interventions for SARS-CoV-2 – exploiting metabolic synergy

Elena Lian1, Gabriela Ramirez1, Carley McAlister1, Brian J. Geiss1, David Paterson2 and Rushika Perera1

1Dept. of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO

2Office of the Vice President for Research, Colorado State University, Fort Collins, CO

COVD-19 is displaying unexpected complications that require unique approaches to therapeutic intervention. Increasing evidence suggest that while monotherapies of FDA approved drugs may have some ameliorating effects they fall short to provide effective intervention. This is primarily due to the unique metabolic interactions in individuals that exacerbate variability to the drug’s response causing idiosyncratic, hyporeactive, hyperreactive or tachyphylaxis manifestations. Two innovative approaches will provide a significant leap forward to improve therapeutic efficacy; i) Identifying synergistic combination therapies that will provide the ability to utilize low-dose interventions that have enhanced efficacy and higher therapeutic indices through synergy and will increase the number of selective therapies in the current pharmacopeia ii) identifying the metabolic impact of drugs on the host will provide insight into alternate modes of action that may interfere with or enhance therapeutic efficacy through synergy or dysergy. These concepts will be discussed supported by preliminary evidence.